pfizer oral glp 1 Phase IIb Data Support Monthly GLP-1 Dosing for Obesity Pfizer punts on one oral

doi: 10.2337/diabetes.54.7.2212 [DOI] [PubMed] [Google Scholar] 154

References: [1] Eli Lilly becomes first drugmaker to hit trillion-dollar m-cap on weight-loss demand boom, November 2025: [2] Orozco-Ruiz et al

to produce over one billion starter doses, according to FDA shipping data

In the vascular system, oxidative stress in diabetes activates ROS-mediated Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling cascades, promoting autophagy in endothelial cells while downregulating HDAC6 expression, which impairs cell migration and adhesion

Enzalutamide triggers Akt and mTOR levels

Is blood work required before starting GLP-1 treatments